DNA mutational profiling in patients with colorectal cancer treated with standard of care reveals differences in outcome and racial distribution of mutations

F Innocenti, W Mu, X Qu, FS Ou, O Kabbarah… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab …
被引用次数：8 相关文章

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations

F Innocenti, W Mu, X Qu, FS Ou… - Journal of clinical …, 2024 - pubmed.ncbi.nlm.nih.gov
Purpose CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab …

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.

F Innocenti, W Mu, X Qu, FS Ou… - Journal of Clinical …, 2023 - europepmc.org
Purpose CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab …

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations

F Innocenti, W Mu, X Qu, FS Ou… - Journal of Clinical …, 2024 - mayoclinic.elsevierpure.com
PURPOSE CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab …

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations

F Innocenti, W Mu, X Qu, FS Ou… - Journal of Clinical …, 2024 - ingentaconnect.com
PURPOSE CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab …

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations

F Innocenti, W Mu, X Qu, FS Ou… - Journal of Clinical …, 2024 - ohsu.elsevierpure.com
PURPOSE CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab …